地西他滨治疗老年急性髓系白血病患者的临床评价  

Clinical evaluation of Decitabine on the treatment of elderly patients with acute myeloid leukemia

作　　者：单学赟[1] 周茉[1] 李小莉[1] 孙乃同[1] 

机构地区：[1]江苏省盐城市第三人民医院血液科,224000

出　　处：《中国综合临床》2016年第8期717-719,共3页Clinical Medicine of China

摘　　要：目的：评价地西他滨为基础的化疗方案治疗老年急性髓系白血病（ AML）的临床效果。方法回顾性分析2013年1月至2015年11月我院收治的老年AML患者的临床资料，根据其是否使用地西他滨分为地西他滨组（10例）和传统方案组（19例），并行疗效评定。结果地西他滨组和传统方案组患者治疗有效率分别为70.0％（7／10）和47.4％（9／19），差异有统计学意义（P＝0.03）；同时两组的中位生存期分别为44.87个月、13.40个月，两组比较差异有统计学意义（ P＝0.04）。两组患者不良反应（粒细胞减少、PLT减少、乏力、心血管事件、呼吸道感染）发生率比较差异无统计学意义（ P＞0.05）。结论国产地西他滨为基础的化疗方案治疗AML效果较好，且延长生存期。Objective To evaluate the clinical effect of Decitabine as the basis of the chemotherapy regimen on the treatment of elderly patients with acute myeloid leukemia（ AML）.Methods The clinical data of elderly patients with AML admitted to the Third People ’ s Hospital of Yancheng from January 2013 to November 2015 were retrospective analyzed.The patients were divided into Decitabine group （ cases ） and the traditional group（19 cases） according to whether or not useed Decitabine,then evaluated the efficacy.Results The overall response rate（ ORR） was 70.0% in 10 patients received decitabine,47.4% in 9 patents of the traditional group, and the difference was significant（ P=0.03）.At the same time,the median survival time of the two groups was 44.87 months and 13.40 months respectively,the difference was statistically significant between the two groups （P=0.04）.There was no significant difference in the incidence of adverse reactions between the two groups （ granulocyte reduction, PLT reduction, fatigue, cardiovascular events, and respiratory tract infections ） （ P〉0.05）.Conclusion The effect of Decitabine as the basis of the chemotherapy regimen on the treatment of AML is better,can prolong the survival time.

关 键 词：地西他滨 急性髓系白血病 老年人 

分 类 号：R733.71[医药卫生—肿瘤]